Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Perpetuation of Premium for New Drug Development Will Depend on Convincing Data: HIB Director General Kikura
October 2, 2012
- Study Group Outlines Plan to Establish Palliative Care Centers at Designated Cancer Treatment Alliance Hospitals
October 1, 2012
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
- HSB to Make “Steady Efforts” Against Lifestyle Diseases: Director General Yajima
September 28, 2012
- Latest Proposal to Discuss Reference Pricing System Gets Cold Shoulder from CSIMC
September 26, 2012
- MHLW Reports 1 Dispensing Error Due to Name Similarity; Almarl Already Renamed
September 24, 2012
- MHLW Issues Notification to Prohibit Dispensing Point Services
September 21, 2012
- MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
- Reimbursement of Generic Drugs Used Off-Label “Not Necessarily Illegal,” Government Says
September 20, 2012
- Half of Hospitals Participating in Network Play Central Role: MHLW FY2011 Survey
September 19, 2012
- MHLW Eyes Introduction of Piecework Payment for Clinical Trials at 54 Hospitals by FY2016
September 18, 2012
- MHLW Budget Request Includes Funds for Database of Information on Patients with Cancer, Lifestyle Diseases
September 18, 2012
- MHLW Calls for Self-Inspections at Japanese Pharmaceutical Firms after “Gutter Oil”-Made Antibiotic Intermediates Found in China
September 14, 2012
- MHLW Instructs Daiichi Sankyo to Issue Blue Letter on Ranmark Following Two Reported Deaths
September 13, 2012
- MEXT Calls for 21 Billion Yen for Special Priority Area of Healthcare Innovation in FY2013 Budget Request
September 12, 2012
- Osaka District Court to Issue Ruling on Actos Patent Suit on Sept. 27
September 12, 2012
- MHLW Issues Q&As on Drug Risk Management Plans to Prefectures
September 12, 2012
- MHLW Notifies of Expected Additional Indications for 3 APIs
September 12, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…